What is the future of PEGylated therapies?

Magdalena Swierczewska, Kang Choon Lee, Seulki Lee

Research output: Contribution to journalArticle

Abstract

The tremendous potential of biologic drugs is hampered by short half-lives in vivo, resulting in significantly lower potency than activity seen in vitro. These short-acting therapeutic agents require frequent dosing profiles that can reduce applicability to the clinic, particularly for chronic conditions. Therefore, half-life extension technologies are entering the clinic to enable improved or new biologic therapies. PEGylation is the first successful technology to improve pharmacokinetic (PK) profiles of therapeutic agents and has been applied in the clinic for over 25 years. Over 10 PEGylated therapeutics have entered the clinic since the early 1990s, and new PEGylated agents continue to expand clinical pipelines and drug patent life. PEGylation is the most established half-life extension technology in the clinic with proven safety in humans for over two decades. Still, it is one of the most evolving and emerging technologies that will be applied for the next two decades.

Original languageEnglish (US)
Pages (from-to)531-536
Number of pages6
JournalExpert Opinion on Emerging Drugs
Volume20
Issue number4
DOIs
StatePublished - Oct 2 2015

Fingerprint

Technology
Life Expectancy
Half-Life
Biological Therapy
Therapeutics
Pharmaceutical Preparations
Pharmacokinetics
Safety
In Vitro Techniques

Keywords

  • half-life extension
  • PEGylation
  • peptide delivery
  • protein delivery

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

What is the future of PEGylated therapies? / Swierczewska, Magdalena; Lee, Kang Choon; Lee, Seulki.

In: Expert Opinion on Emerging Drugs, Vol. 20, No. 4, 02.10.2015, p. 531-536.

Research output: Contribution to journalArticle

Swierczewska, Magdalena ; Lee, Kang Choon ; Lee, Seulki. / What is the future of PEGylated therapies?. In: Expert Opinion on Emerging Drugs. 2015 ; Vol. 20, No. 4. pp. 531-536.
@article{d6671fb5d9054fb39ef4b6e178dee018,
title = "What is the future of PEGylated therapies?",
abstract = "The tremendous potential of biologic drugs is hampered by short half-lives in vivo, resulting in significantly lower potency than activity seen in vitro. These short-acting therapeutic agents require frequent dosing profiles that can reduce applicability to the clinic, particularly for chronic conditions. Therefore, half-life extension technologies are entering the clinic to enable improved or new biologic therapies. PEGylation is the first successful technology to improve pharmacokinetic (PK) profiles of therapeutic agents and has been applied in the clinic for over 25 years. Over 10 PEGylated therapeutics have entered the clinic since the early 1990s, and new PEGylated agents continue to expand clinical pipelines and drug patent life. PEGylation is the most established half-life extension technology in the clinic with proven safety in humans for over two decades. Still, it is one of the most evolving and emerging technologies that will be applied for the next two decades.",
keywords = "half-life extension, PEGylation, peptide delivery, protein delivery",
author = "Magdalena Swierczewska and Lee, {Kang Choon} and Seulki Lee",
year = "2015",
month = "10",
day = "2",
doi = "10.1517/14728214.2015.1113254",
language = "English (US)",
volume = "20",
pages = "531--536",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - What is the future of PEGylated therapies?

AU - Swierczewska, Magdalena

AU - Lee, Kang Choon

AU - Lee, Seulki

PY - 2015/10/2

Y1 - 2015/10/2

N2 - The tremendous potential of biologic drugs is hampered by short half-lives in vivo, resulting in significantly lower potency than activity seen in vitro. These short-acting therapeutic agents require frequent dosing profiles that can reduce applicability to the clinic, particularly for chronic conditions. Therefore, half-life extension technologies are entering the clinic to enable improved or new biologic therapies. PEGylation is the first successful technology to improve pharmacokinetic (PK) profiles of therapeutic agents and has been applied in the clinic for over 25 years. Over 10 PEGylated therapeutics have entered the clinic since the early 1990s, and new PEGylated agents continue to expand clinical pipelines and drug patent life. PEGylation is the most established half-life extension technology in the clinic with proven safety in humans for over two decades. Still, it is one of the most evolving and emerging technologies that will be applied for the next two decades.

AB - The tremendous potential of biologic drugs is hampered by short half-lives in vivo, resulting in significantly lower potency than activity seen in vitro. These short-acting therapeutic agents require frequent dosing profiles that can reduce applicability to the clinic, particularly for chronic conditions. Therefore, half-life extension technologies are entering the clinic to enable improved or new biologic therapies. PEGylation is the first successful technology to improve pharmacokinetic (PK) profiles of therapeutic agents and has been applied in the clinic for over 25 years. Over 10 PEGylated therapeutics have entered the clinic since the early 1990s, and new PEGylated agents continue to expand clinical pipelines and drug patent life. PEGylation is the most established half-life extension technology in the clinic with proven safety in humans for over two decades. Still, it is one of the most evolving and emerging technologies that will be applied for the next two decades.

KW - half-life extension

KW - PEGylation

KW - peptide delivery

KW - protein delivery

UR - http://www.scopus.com/inward/record.url?scp=84951906663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951906663&partnerID=8YFLogxK

U2 - 10.1517/14728214.2015.1113254

DO - 10.1517/14728214.2015.1113254

M3 - Article

C2 - 26583759

AN - SCOPUS:84951906663

VL - 20

SP - 531

EP - 536

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 4

ER -